1. In Vivo
  2. >>ESG

The E in ESG: Medtechs Are Getting To Grips With The ‘True Purpose’ Of Carbon Zero

Late starters health care and medtech are now making progress in the race to zero

 
• By Ashley Yeo

BD and Boston Scientific exemplify the approach of “big medtech” as it knuckles down to meet global climate change responsibilities. But the industry will have to work together with health systems to achieve the larger race to zero goals – especially those of scope 3.  

Net Zero
• Source: Shutterstock

The medtech industry and health care sector in general have admittedly been slow starters in joining the race to carbon neutrality across their businesses. But much catch-up work is now ongoing, as evidenced from a recent UK-based industry conference on priorities and progress.

The UK earned bragging rights on the drive to sustainability in health care when its National Health Service (NHS) in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from ESG

RESILIENCE Initiative Navigates The World Of Making Medicines Through VR Technology

 
• By Anabel Costa-Ferreira

The process of manufacturing medicines can often be complex, expensive and harmful to the environment. Initiatives like RESILIENCE UK are seeking to simplify this process, utilizing VR technology to create a more sustainable learning environment for both students and companies.

Cracking Through ‘The Bamboo Ceiling’: East Asians Reach For Pharma Leadership

 
• By Brian Yang

Despite the significant presence of East Asian professionals in the pharmaceutical industry, their representation in top leadership roles remains disproportionately low. This disparity can be attributed to cultural bias, limited access to influential networks, and systemic barriers within corporate structures.

Infographic: Analyzing The Gap In Women’s Health Care

 
• By Anabel Costa-Ferreira

Looking at a recent McKinsey report alongside our Evaluate data, the below infographic provides insight into the investment scene of pharma and raises questions as to how the industry is seemingly yet to seize the opportunity in women's health.

Growing Calls For Labelling Changes With Obesity Patients In Mind

 
• By Ed Silverman

Despite significant investments in weight loss treatments, pharmaceutical companies face criticism for neglecting to study their drugs in obese patients, possibly leading to incomplete labeling and patient risks, prompting calls for the FDA to enforce more inclusive clinical trials and updated drug information.

More from In Vivo

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By Lisa Takagi

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.

Rising Leaders 2025: Ovid’s Meg Alexander On Neurology’s Next Frontier

 
• By Jo Shorthouse

Ovid Therapeutics' president and COO Meg Alexander is leading the company’s strategic pivot toward innovative neurological treatments, potentially creating a new class of medicines for rare neurological disorders.

The Goldilocks Isotope: Perspective Therapeutics’ ‘Just Right’ Alpha Radiotherapeutic

 
• By David Wild

Thijs Spoor's bet on lead-212 is paying off as Perspective Therapeutics advances three clinical programs with promising early efficacy signals and a comprehensive manufacturing strategy.